Table 1 Baseline characteristics of rheumatoid arthritis (RA) patients and the controls
Variable | RA patients (n = 100) | Controls (n = 100) | P value | ||
|---|---|---|---|---|---|
Demographic | Age (Years) | Mean ± SD | 43 ± 10.3 | 40.5 ± 11.2 | 0.1 |
Sex | (Male:female) | (27:73) | (28:72) | 0.87 | |
Body mass index (kg/m2) | Mean ± SD | 27.03 ± 2.95 | 26.83 ± 3.02 | 0.62 | |
Clinical | Disease duration (years) | Median (IQR) | 6 (3–10.5) | – | – |
Morning stiffness duration (min) | Median (IQR) | 25 (15–30) | – | – | |
Tender joint count | Median (IQR) | 4 (2–9) | – | – | |
Swollen joint count | Median (IQR) | 1 (0–3) | – | – | |
Cutaneous manifestations | n (%) | 22 (22%) | – | – | |
Pulmonary involvement | n (%) | 18 (18%) | – | – | |
Ocular involvement | n (%) | 13 (13%) | – | – | |
Laboratory | ESR (mm/1st h) | Median (IQR) | 25.5 (15–35) | – | – |
C-reactive protein (mg/l) | Median (IQR) | 8 (3.35–16) | – | – | |
Hemoglobin (g/dL) | Mean ± SD | 11.2 ± 1.71 | 13.72 ± 1.52 | < 0.001 | |
White blood cells (x103/ul3) | Mean ± SD | 7.47 ± 1.98 | 7.34 ± 1.53 | 0.01 | |
Neutrophils (× 103/ul3) | Mean ± SD | 4.46 ± 1.41 | 3.96 ± 0.98 | < 0.001 | |
dNLR | Median (IQR) | 1.5(1.175–1.885) | 1.12 (0.985–1.33) | < 0.001 | |
Platelets (× 103/ul3) | Mean ± SD | 280.4 ± 97.25 | 270.01 ± 81.61 | 0.41 | |
Rheumatoid factor (IU/mL) | Median (IQR) | 32 (24–74) | – | – | |
Anti-CCP (IU/mL) | Median (IQR) | 76 (31–153) | – | – | |
Albumin (g/dL) | Median (IQR) | 3.9 (3.5–4.35) | 4.22 (3.91–4.73) | < 0.001 | |
Albumin-dNLR score | Median (Range) | 1 (0–2) | 0 (0–2) | < 0.001 | |
DAS28-ESR | Median (IQR) | 3.8 (2.8–4.42) | – | – | |
MSUS | Greyscale | Median (IQR) | 6 (2–11.5) | – | – |
Power Doppler | Median (IQR) | 1 (0–3) | – | – | |
Total 12 joints US score | Median (IQR) | 6.5 (2–14.5) | – | – | |
Medications | NSAIDs | n (%) | 42 (42%) | – | – |
Corticosteroids | n (%) | 58 (58%) | – | – | |
Hydroxychloroquine | n (%) | 89 (89%) | – | – | |
Methotrexate | n (%) | 74 (74%) | – | – | |
Leflunomide | n (%) | 31 (31%) | – | – | |
Sulfasalazine | n (%) | 11 (11%) | – | – | |
Biological agents | n (%) | 16 (16%) | – | – | |